Vitamin K

Quick links to important sections

Vitamin K

Method of action: Antihemorrhagics

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vitamin K

Property Description
Active ingredient Phytomenadione (Vitamin K₁/Phylloquinone)
Form Solution for injection, Oral solution, Tablet
Pharmacological class Antihemorrhagic agent (Hemostatic)
General purpose Restores the body’s ability to clot blood
Origin Naturally occurring K₁, used in high-purity synthetic preparations

What Type of Medicine is Vitamin K (Phytomenadione)?

Vitamin K, known by its International Nonproprietary Name (INN) Phytomenadione, is officially classified as an antihemorrhagic agent and belongs to the wider pharmacological group of hemostatics. The medicine's active ingredient is chemically identical to Vitamin K₁ or Phylloquinone, which is an essential fat-soluble vitamin. This classification is clinically recognized for its specific mechanism. Phytomenadione is prepared as a high-purity, often synthetic, single-ingredient product. While the naturally occurring K₁ is found in plants, the pharmaceutical preparations are designed for precise therapeutic use. It is supplied as a sterile solution for injection for parenteral administration and as an oral solution or tablet for ingestion, with injectable forms often prepared as aqueous colloidal solutions for enhanced bioavailability in critical settings.


What is the General Purpose of This Essential Coagulation Factor?

The general purpose of administering Phytomenadione is to restore or maintain the body's impaired ability to form blood clots effectively. This function is critical because Vitamin K is required to ensure the biological activation of four key coagulation factors in the liver, specifically factors II, VII, IX, and X. This medicine is crucial for making the proteins needed for clotting. By acting as a crucial cofactor for the production of these necessary clotting proteins, the medication quickly restores the essential elements of the blood clotting cascade. Its therapeutic action acts as a rapid counterbalance to deficiencies, such as those caused by malabsorption syndromes, providing a vital mechanism to prevent excessive or uncontrolled bleeding.

What side effects are possible with Vitamin K?

Possible Side Effects and Safety Information

The safety profile of Phytomenadione (Vitamin K) is formally documented in regulatory sources and is categorized by the system affected and the frequency of occurrence. The most critical safety consideration is the risk of severe hypersensitivity reactions, including anaphylactic shock and cardiac or respiratory arrest, which are officially classified as rare events but are a major concern, particularly following intravenous (IV) or intramuscular (IM) administration.

Less severe and more commonly noted adverse reactions include transient flushing sensations, a peculiar sensation of taste, and localized pain or swelling at the injection site. These are officially grouped under physiological system classes such as Gastrointestinal and Skin and Subcutaneous Tissue disorders.

System-Organ Class Key Adverse Reactions (Regulatory Listing)
Immune/Vascular Severe hypersensitivity, hypotension, cardiac arrest, cyanosis.
Skin/Subcutaneous Injection site pain/swelling, rarely atrophy, necrosis, or scleroderma-like lesions.
Gastrointestinal Transient flushing, peculiar sensation of taste.
Hepatobiliary Hyperbilirubinemia (primarily in neonates).

Population-Specific Safety: The regulatory label carries specific warnings for neonates regarding the risk of hyperbilirubinemia (jaundice) and hemolysis, especially if doses exceed established guidelines. Safety cautions for older adults reflect the potential for reduced physiological function, recommending cautious dose selection. Severe reactions, including cutaneous events like scleroderma-like lesions, have been reported with a delayed onset, sometimes occurring days or months after parenteral exposure. The medicine is contraindicated in individuals with known hypersensitivity to the active substance.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Phytomenadione overdose is defined by two primary risks: the danger of a life-threatening systemic reaction and the consequences of overzealous therapy. The most severe concern is the potential for a fatal and severe hypersensitivity reaction (anaphylactoid event), principally associated with the injectable form. Manifestations requiring immediate medical attention include physical signs such as dizziness, transient flushing, profuse sweating, brief hypotension, tachycardia (rapid pulse), dyspnea (trouble breathing), cyanosis, or shock. These symptoms necessitate immediate action.

Regulatory documents explicitly require that immediate medical attention and emergency services must be sought if any of these severe systemic signs are observed. Upon a suspected overdose or severe reaction, discontinuation of the medicine is mandatory, and management involves symptomatic and supportive treatment. No specific antidote is known for direct Phytomenadione toxicity.

A secondary overdose concern relates to excessive doses, which can lead to overzealous therapy. This risk results in the swift over-correction of coagulation, potentially causing thromboembolic phenomena. For this reason, continuous monitoring of the International Normalized Ratio (INR) is required to assess and prevent hypercoagulability. Furthermore, specific to infants, doses exceeding recommended limits are associated with an increased risk of hyperbilirubinemia and jaundice, a key population-specific consideration noted in official labels.

Therapeutic Uses of Vitamin K

What Vitamin K Treats: Main Uses and Benefits

Vitamin K is used across several relevant therapeutic domains, primarily managing symptoms related to impaired blood clotting and providing support for skeletal health.

Managing Symptoms Associated with Bleeding

It is commonly used to support the body's clotting ability, which may assist in managing symptoms related to uncontrolled bleeding and easy bruising. A deficiency of this substance can cause too much bleeding. It helps address issues like persistent nosebleeds, bleeding gums, or the tendency to bruise frequently, contributing to the patient's comfort and assisting with the management of blood loss risk associated with deficiency.

The relevant scenarios for use include: supporting patients with deficiency-related bleeding symptoms, addressing the effects of certain oral blood thinners, and managing bleeding risks in newborns.

Prophylactic Support for Newborns and Bone Structure

Vitamin K is routinely administered to all infants at birth to manage the risk of a specific bleeding disorder. Beyond blood health, Vitamin K is relevant for the body's processes that support the maintenance of strong bone tissue. This contributes to the long-term stability of the skeleton.


Quick Fact: Relevant for Easy Bleeding Symptoms

Regulatory References

  1. NIH MedlinePlus overview of Vitamin K

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Vitamin K (Phytomenadione) — official regulatory information


Eligibility Scope

Populations for whom use is allowed (as stated in label): Adults with acquired hypoprothrombinemia due to oral anticoagulants or conditions like obstructive jaundice. Neonates and newborns for prophylaxis and treatment of Vitamin K-Deficiency Bleeding (VKDB).

Populations for whom use is not recommended (if applicable): Infants under one year old for concentrated adult formulations; preterm or low birth weight infants for oral prophylaxis.

Populations for whom use is contraindicated: Patients with known hypersensitivity to phytonadione or any component. Patients receiving anticoagulant therapy via the intramuscular (IM) route.

Age-related eligibility rules: Neonates are approved. Safety and effectiveness are not established for certain formulations in pediatric patients (6 months to 17 years). Older adults require cautious dose selection.

Condition-specific eligibility rules: Patients with severe liver impairment require caution; repeated large doses are not warranted if the response is unsatisfactory.

Pregnancy and lactation eligibility status (if explicitly documented): Use is conditional and only permitted if clearly needed. Preservative-free formulations are recommended for both.

Eligibility-related restrictions: Neonates and infants must use preservative-free formulations due to a significant risk associated with the benzyl alcohol preservative.


Eligibility Classifications (High-Level)

Eligibility severity classification (as defined in official documents): Absolute Contraindication: Hypersensitivity. Use Not Established: Pediatric patients (6 months to 17 years). Restricted/Conditional Use: Neonates, pregnant/nursing women, and severe hepatic impairment.

Regulatory basis (EMA / FDA / etc.): Primary basis is derived from Contraindications, Warnings and Precautions, and Use in Specific Populations sections of regulatory documents.

Eligibility-context constraints (as defined in official documents): Formulation type (preservative-free) and route of administration (avoiding IM in anticoagulated patients) are mandatory constraints.


Resulting Eligibility Structure

Official eligibility statements:

  • The medicine is contraindicated in patients with a known hypersensitivity to phytonadione.
  • The safety and effectiveness have not been established in pediatric patients aged 6 months to 17 years.
  • Neonates and infants must use preservative-free formulations.

Connection to the overall eligibility profile (2–4 sentences): Official regulatory documents define who can and cannot use the medicine by establishing clear absolute contraindications (hypersensitivity) and severe restrictions tied to patient population (neonates must use preservative-free formulations). Furthermore, the eligibility profile explicitly permits use in patients whose clotting deficiency stems from specific comorbid conditions (like malabsorption), while simultaneously imposing cautions for vulnerable populations such as the elderly.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile of Phytomenadione (Vitamin K) is primarily defined by its effects on blood coagulation factors and its dependence on gastrointestinal absorption.


Pharmacodynamic and Antagonist Interactions

The main documented pharmacodynamic interaction is the antagonism of prothrombin-depressing oral anticoagulants, suchably Warfarin. This reversal of the anticoagulant effect may result in a state of temporary resistance if oral anticoagulant therapy is later reinstituted. Importantly, Phytomenadione will not counteract the anticoagulant action of heparin, which necessitates alternative management for heparin-related over-anticoagulation.


Exposure-Modifying and Deficiency Interactions

Interactions that reduce systemic exposure involve substances that inhibit uptake. Agents such as bile acid sequestrants (e.g., Cholestyramine) and mineral oil may decrease the systemic exposure of oral Phytomenadione by preventing its gastrointestinal absorption. Regulatory guidance recommends that the oral administration of these substances and Vitamin K be separated by at least two hours to mitigate this reduction.

Other medicinal products are documented to interfere with the body's natural Vitamin K status. Broad-spectrum antibacterial therapies may induce a risk of hypoprothrombinemia by disrupting the normal intestinal flora responsible for endogenous Vitamin K synthesis. Similarly, salicylates are also associated with interference with Vitamin K metabolism. Official labeling indicates that caution may be necessary for patients with impaired hepatic function, as this condition can affect the body's utilization of Vitamin K.

Mechanism of Action

️ The Core Mechanism: gamma-Carboxylation and Cofactor Function

Vitamin K (Phytomenadione) is an essential cofactor for the enzyme gamma-glutamyl carboxylase (GGCX). This enzyme modifies precursor proteins by adding a second carboxylic acid group to specific residues (Gla), enabling the resulting Vitamin K-Dependent Proteins (VKDPs) to efficiently bind calcium ions ( Ca^2+). This action is sustained by a tight recycling loop driven by VKOR, which regenerates the active cofactor.

Causal Chain: From Molecular Change to Hemostatic Balance

The calcium-binding capability imparted by the gamma-carboxylation of VKDPs is the functional switch that allows coagulation factors (like Factors II, VII, IX, and X) to assemble on cell membranes at injury sites. This molecular cascade is necessary for the execution of the full clotting cascade, which establishes the molecular foundation for hemostatic balance. The mechanism also activates non-clotting proteins involved in the regulation of vascular and bone calcium dynamics.

Mechanism Limitation: Vulnerability to VKOR Inhibition

The mechanism is physiologically constrained by its dependence on the VKOR enzyme. Drugs like Warfarin competitively inhibit this recycling step, functionally depleting the active Vitamin K cofactor. This prevents the gamma-carboxylation of newly synthesized factors, resulting in the production of non-functional clotting proteins that cannot bind calcium.

Dosage and Administration Information

Administration Scope and Routes

Phytomenadione (Vitamin K₁) is administered through several routes, including subcutaneous (SC), intravenous (IV), intramuscular (IM), and oral (PO) forms, depending on the therapeutic need and available preparation. For injectable solutions, the subcutaneous route is typically preferred whenever feasible. If intravenous administration is unavoidable, the drug must be injected very slowly, with a rate that should not exceed 1 mg per minute.

Official Dosing and Frequency

Standard adult parenteral dosing for conditions such as anticoagulant-induced hypoprothrombinemia usually begins in the range of 2.5 mg to 10 mg, though single doses may be increased to 25 mg to 50 mg in select instances. Following the initial parenteral dose, subsequent doses are conditional, typically determined by laboratory metrics like the International Normalized Ratio (INR), and may be repeated in 6 to 8 hours if the INR has not shortened satisfactorily. For oral administration, repeat dosing, if needed, may be scheduled 12 to 48 hours after the initial dose.

Procedural and Population-Specific Rules

For neonatal prophylaxis of bleeding disorders, a single dose of 0.5 mg to 1 mg is administered intramuscularly or subcutaneously within one hour of birth. Oral administration requires the presence of bile salts for adequate absorption; if the natural bile supply is deficient, bile salt supplementation must be provided with the oral form. The injection solution may be diluted with standard solutions such as 0.9% Sodium Chloride or 5% Dextrose, and must be protected from light at all times.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Vitamin K

Evidence for Managing Excessive Anticoagulation

Research has explored how Phytomenadione was studied for its role in the change in blood clotting markers, specifically the International Normalized Ratio (INR), for adults taking oral blood thinners. Randomized Controlled Trials (RCTs) have monitored patients to see how different forms and doses relate to the speed at which this INR marker changes toward a pre-defined target range. Findings describe patterns observed in the studies related to INR change, and evidence was evaluated in patients with active bleeding or those scheduled for urgent procedures requiring alteration of their anticoagulation status. Long-term outcomes are not well characterized regarding the stability of the reversal over several months, and comparative evidence is still emerging about assessing the long-term incidence of thromboembolic events after reversal.

Evidence for Preventing Bleeding in Newborns

Vitamin K was studied for its role in reducing the incidence of Vitamin K Deficiency Bleeding (VKDB) in infants. The evidence base includes historical comparative trials and large national surveillance studies that monitor the rates of this condition. Studies were evaluated in full-term and premature infants, and surveillance data describes patterns where the frequency of VKDB was reported to be lower in populations where intramuscular administration was observed in practice. The comparative evidence is lacking regarding different oral regimens versus the intramuscular route in relation to late-onset VKDB, and modern placebo-controlled trials are not conducted due to ethical constraints.

Overview of Studies on Bone Tissue Support

Vitamin K was evaluated in research exploring outcomes related to systemic imbalance in bone health, primarily in post-menopausal women. These largely involved long-term supplementation trials monitoring changes in Bone Mineral Density (BMD) and the incidence of fractures. The findings were inconsistent across available supplementation trials. The results apply only to the populations studied, meaning the applicability to other groups remains unclear. Furthermore, the optimal form and dose for its role in research exploring long-term outcomes related to bone tissue is not fully established.

Key Studies & References

  1. ACC Consensus on Management of Anticoagulant-Related Bleeding (2020)
  2. PHYTONADIONE INJECTABLE EMULSION, USPAqueous Colloidal Solution of Vitamin K1 (DailyMed/FDA Monograph)

Frequently Asked Questions (FAQ)

Common questions about Vitamin K (FAQ)


Q: Why is Vitamin K often given to newborns?

According to official public health guidelines, Vitamin K is routinely administered to newborns to help prevent a serious bleeding condition known as Vitamin K Deficiency Bleeding (VKDB). Infants are considered to be at high risk for VKDB shortly after birth, and this measure is intended to support the baby's clotting ability.


Q: Does taking Vitamin K cause blood clots?

Official regulatory documents indicate that the injectable form of Vitamin K is not classified as a clotting agent itself. However, reversing the effects of certain blood thinners (anticoagulants) with Vitamin K could result in a change in blood clotting ability toward pre-existing levels.


Q: Can certain medical conditions stop me from being eligible to use Vitamin K?

Official regulatory information states that the medicine may be used to treat blood clotting problems resulting from specific conditions, such as obstructive jaundice (a liver problem) or malabsorption syndromes (difficulty absorbing nutrients). Conversely, the medicine is contraindicated in individuals with known hypersensitivity to the active substance.


Q: Why are people often confused about Vitamin K and blood thinners?

The confusion often arises because the medicine is used to directly counteract, or antagonize, the effect of certain oral blood thinners like Warfarin. These thinners work by blocking Vitamin K's action in the body. Administering Vitamin K can therefore quickly reverse the thinning effect, which can be critical in situations requiring a change in clotting ability.


Q: How quickly can Vitamin K reverse the effects of certain medications?

According to official product information, after an injection is given, blood clotting factors typically begin to increase within one to two hours. For oral administration, the expected therapeutic effect generally begins slightly later, within six to ten hours.


Q: Is Vitamin K a prescription drug or can I get it over the counter?

Vitamin K is available in the United States in two regulatory categories. It is available as an over-the-counter (OTC) dietary supplement in various forms. It is also available as a prescription medication, with the injectable form being classified as a prescription product used in clinical settings.


Q: What is the difference between Vitamin K1 and Vitamin K2?

Official scientific literature describes Vitamin K as a group of compounds. Vitamin K1 (Phylloquinone) is the form primarily synthesized by plants and is the active ingredient in most pharmaceutical preparations for clotting purposes. Vitamin K2 (Menaquinone) is a family of compounds primarily produced by bacteria in the gut.


Q: Is it possible to take too much Vitamin K?

Regulatory sources indicate that Vitamin K1 (Phytonadione), which is the primary form used in medicine and supplements, is not toxic when consumed orally, even in high amounts. Toxicity has been reported with the synthetic precursor known as Menadione (Vitamin K3), which is not currently used in official pharmaceutical preparations.


Q: How long does it take for Vitamin K to start working?

After parenteral (injected) administration, blood clotting factors typically begin to increase within one to two hours. For oral administration, the expected therapeutic effect generally begins within six to ten hours, according to official product information.


Q: If I eat a lot of leafy greens, do I need Vitamin K supplements?

Leafy greens are a natural source of Vitamin K, and the body's gut bacteria also contribute to the overall supply. The necessity for a supplement is typically based on factors beyond diet alone, such as the presence of a clinical deficiency, malabsorption issues, or if an individual is taking specific medications.


Q: What is the connection between Vitamin K and bone health?

The physiological connection is that Vitamin K is required to activate specific proteins, such as osteocalcin and Matrix Gla-protein. These proteins are involved in regulating calcium dynamics related to bone tissue.


Q: Are there different forms of Vitamin K medication (like pills vs. injections)?

Yes, official dosage forms include a sterile solution for injection, which is used for parenteral administration (given other than by the mouth), as well as oral dosage forms such as tablets and oral solutions for ingestion.


Q: What does research say about Vitamin K and heart health?

Research has explored the potential of certain forms of Vitamin K, particularly Vitamin K2, to activate proteins that are involved in regulating calcium within vascular tissue. This function is being studied for its relationship to regulating calcium dynamics in vascular tissue.


Q: How long does Vitamin K stay in the body?

Official scientific literature indicates that after Vitamin K is absorbed and utilized, the excess is rapidly catabolized (broken down). It is then primarily excreted from the liver in bile.


Q: Is Vitamin K used for conditions other than bleeding disorders?

While the primary therapeutic purpose of the medicine is to restore the body’s ability to clot blood, the vitamin itself is also essential for activating proteins that are involved in supporting bone health throughout the body.


Q: Does Vitamin K have different names in other countries?

The medicine is internationally known by its official names, such as the International Nonproprietary Name (INN) Phytomenadione. This name is chemically identical to the naturally occurring Vitamin K or Phylloquinone, which helps standardize its use worldwide.


Q: Is Vitamin K considered a dietary supplement or a medication?

Vitamin K exists in both categories. It is available as an over-the-counter dietary supplement. However, the higher-dose, sterile injectable formulation is regulated as a prescription medication and is typically administered by a healthcare professional.


Q: Are there certain groups of people who are more likely to have a Vitamin K deficiency?

Groups at increased risk for low levels include newborns, due to poor transfer from the mother during pregnancy, and people with conditions that cause malabsorption, such as certain chronic digestive disorders. Individuals taking medications that interfere with its absorption or metabolism may also be at increased risk.


Q: Is there a link between cystic fibrosis and needing Vitamin K?

Medical literature has documented a link between Vitamin K deficiency and issues observed in patients with cystic fibrosis. This link exists because cystic fibrosis is a condition that is associated with impaired absorption of fat-soluble vitamins, including Vitamin K.


Q: Why do I hear conflicting things about Vitamin K in different countries?

Differences in information may arise due to variations in the specific regulatory guidance issued by different national health authorities, such as the FDA or the EMA, regarding approved uses or safety precautions. Furthermore, clinical practices and research findings can vary between countries and populations.


Q: Does Vitamin K have an expiration date I should watch out for?

As a regulated medicine, Vitamin K has an expiration date that is printed on the product packaging and must be respected to ensure stability and potency. Official storage instructions state that the product must be kept in its original carton and protected from light.


Q: Is it normal to feel dizzy or lightheaded after receiving a Vitamin K shot?

Rare instances of dizziness and lightheadedness have been noted as adverse reactions, particularly following injected administration. Lightheadedness is noted as an adverse reaction, which may be associated with signs such as hypotension (low blood pressure), particularly following injection.


Q: What kinds of symptoms are associated with Vitamin K deficiency?

Symptoms associated with a deficiency may include a tendency to bruise easily or prolonged bleeding. In severe cases like Vitamin K Deficiency Bleeding (VKDB), observed primarily in infants, symptoms can include bleeding in the skin or gastrointestinal tract.


Q: Why is Vitamin K intake important for people taking certain seizure medications?

Official medical literature indicates that certain anticonvulsant medications (used to treat seizures) may interfere with Vitamin K metabolism. This can lead to a state where the body may have difficulty utilizing the vitamin.

How should Vitamin K be stored and disposed of?

How to Store and Dispose of Vitamin K (Phytonadione)

Storage and disposal must align with regulatory requirements to maintain product stability and safety. Vitamin K must be stored at controlled room temperature, typically 20 C to 25 C. The product must be protected from light and stored in the original carton.

Storage Constraints

Freezing is prohibited; the solution must not be used if it appears cloudy or contains precipitate. It must always be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired product, including any remaining portion of single-use injectable solutions, must be disposed of according to local requirements. Used needles and syringes must be safely placed in a designated sharps disposal container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Vitamin K found in:

A-Z Index: